Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified in a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non-Hodgkin lymphomas.
The function of the full-length ALK receptor is still poorly characterized. Recent data suggest that ALK is involved in neuronal cell differentiation and regeneration, synapse formation and muscle cell migration.
Recently, the interest on ALK in oncology has increased considerably, following the discovery of ALK translocations in a fraction of non-small-cell lung cancers and in other solid tumours.
In cancers, all translocations involving ALK produce fusion proteins with constitutive tyrosine kinase activity that in most cases derives from spontaneous dimerization induced by the different fusion partners.
Constitutive ALK activity in cancers results in the activation of several downstream pathways that are shared with other tyrosine kinases. Many of these pathways have already been characterized.
Constitutive ALK signalling induces cell transformation in vitro and in vivo by controlling key cellular processes such as cell-cycle progression, survival, cell migration and cell shaping.
ALK represents an attractive target for innovative combination therapies based on selective small-molecule inhibitors of its tyrosine kinase activity or on its use as an oncoantigen for tumour vaccination.
Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas. The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many molecular mechanisms. In this Review, we will analyse how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacological tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.
Your institute does not have access to this article
Open Access articles citing this article.
AGE/RAGE axis regulates reversible transition to quiescent states of ALK-rearranged NSCLC and pancreatic cancer cells in monolayer cultures
Scientific Reports Open Access 14 June 2022
Leukemia Open Access 08 June 2022
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer
Journal of Experimental & Clinical Cancer Research Open Access 29 March 2022
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jaffe, E. S., Harris, N. L., Stein, H. & Vardiman, J. W. World Health Organization Classification of Tumors: Tumors of the Haematopoietic and Lymphoid Tissues (International Agency for Research on Cancer, Lyon, 2001).
Stein, H. et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed–Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66, 848–858 (1985).
Stein, H. et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96, 3681–3695 (2000).
Sandlund, J. T. et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 12, 895–898 (1994).
Kadin, M. E. & Morris, S. W. The t(2;5) in human lymphomas. Leuk. Lymphoma 29, 249–256 (1998).
Rizvi, M. A., Evens, A. M., Tallman, M. S., Nelson, B. P. & Rosen, S. T. T-cell non-Hodgkin lymphoma. Blood 107, 1255–1264 (2006).
Savage, K. S. Peripheral T-cell lymphomas. Blood Rev. 4, 201–216 (2007).
Fischer, P. et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene. Blood 72, 234–240 (1988).
Benz-Lemoine, E. et al. Malignant histiocytosis: a specific t(2;5)(p23;q35) translocation? Review of the literature. Blood 72, 1045–1047 (1988).
Mason, D. Y. et al. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br. J. Haematol. 74, 161–168 (1990).
Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281–1284 (1994). This is the first paper to describe the cloning of the ALK gene in the chromosomal breakpoints that are associated with the balanced t(2;5)(p23;q35) chromosomal translocation in ALCL.
Medeiros, L. J. & Elenitoba-Johnson, K. S. Anaplastic large cell lymphoma. Am. J. Clin. Pathol. 127, 707–722 (2007).
Benharroch, D. et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91, 2076–2084 (1998).
Ladanyi, M. & Cavalchire, G. Molecular variant of the NPM–ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site. Genes Chromosomes Cancer 15, 173–177 (1996).
Chan, P. K. & Chan, F. Y. Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. Biochim. Biophys. Acta 1262, 37–42 (1995).
Liu, Q. R. & Chan, P. K. Formation of nucleophosmin/B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein. Eur. J. Biochem. 200, 715–721 (1991).
Bischof, D., Pulford, K., Mason, D. Y. & Morris, S. W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell Biol. 17, 2312–2325 (1997).
Grisendi, S., Mecucci, C., Falini, B. & Pandolfi, P. P. Nucleophosmin and cancer. Nature Rev. Cancer 6, 493–505 (2006).
Hernandez, L. et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am. J. Pathol. 160, 1487–1494 (2002).
Colleoni, G. W. et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am. J. Pathol. 156, 781–789 (2000).
Ma, Z. et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95, 2144–2149 (2000).
Touriol, C. et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95, 3204–3207 (2000).
Tort, F. et al. Molecular characterization of a new ALK translocation involving moesin (MSN–ALK) in anaplastic large cell lymphoma. Lab. Invest. 81, 419–426 (2001).
Ventura, R. A. et al. Centrosome abnormalities in ALK-positive anaplastic large-cell lymphoma. Leukemia 18, 1910–1911 (2004).
Armstrong, F., Lamant, L., Hieblot, C., Delsol, G. & Touriol, C. TPM3–ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur. J. Cancer 43, 640–646 (2007).
Maes, B. et al. The NPM–ALK and the ATIC–ALK fusion genes can be detected in non-neoplastic cells. Am. J. Pathol. 158, 2185–2193 (2001).
Trumper, L., Pfreundschuh, M., Bonin, F. V. & Daus, H. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals. Br. J. Haematol. 103, 1138–1144 (1998).
Basecke, J. et al. Transcription of AML1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia. Blood 100, 2267–2268 (2002).
Bose, S., Deininger, M., Gora-Tybor, J., Goldman, J. M. & Melo, J. V. The presence of typical and atypical BCR–ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92, 3362–3367 (1998).
Graninger, W. B., Seto, M., Boutain, B., Goldman, P. & Korsmeyer, S. J. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J. Clin. Invest. 80, 1512–1515 (1987).
Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–665 (2005).
Delsol, G. et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89, 1483–1490 (1997). First description of the presence of ALK protein in lymphomas that are different from ALCL, that is, large B-cell lymphomas.
Kuefer, M. U. et al. Retrovirus-mediated gene transfer of NPM–ALK causes lymphoid malignancy in mice. Blood 90, 2901–2910 (1997). This paper demonstrates for the first time the direct pathogenetic role for the NPM–ALK fusion tyrosine kinase in human lymphomas by using a retroviral gene transfer mouse model.
Lange, K. et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 22, 517–527 (2003).
Chiarle, R. et al. NPM–ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101, 1919–1927 (2003). Development of the first mouse model of ALK-induced lymphomagenesis by targeted expression of human NPM–ALK in T cells.
Jager, R. et al. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res. 25, 3191–3196 (2005).
Chiarle, R. et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Med. 11, 623–629 (2005). This is the first genetic study that directly shows, through gene ablation, that STAT3 is required for cellular transformation and/or for tumour survival and growth of lymphoid cells expressing NPM–ALK. It also suggests the basis for therapeutic strategies directed against STAT3 in ALCL.
Turner, S. D. & Alexander, D. R. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 19, 1128–1134 (2005).
Turner, S. D., Tooze, R., Maclennan, K. & Alexander, D. R. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22, 7750–7761 (2003).
Dirks, W. G. et al. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer 100, 49–56 (2002).
Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007). First description of EML4 – ALK fusion gene in a subset of lung cancers. These cancers are mutually exclusive from those that harbour EGFR mutations.
Perez-Pinera, P., Chang, Y., Astudillo, A., Mortimer, J. & Deuel, T. F. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem. Biophys. Res. Commun. 358, 399–403 (2007).
Griffin, C. A. et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2776–2780 (1999). Description of the first known fusion involving ALK in non-haematopoietic tumours.
Lawrence, B. et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 157, 377–384 (2000).
Coffin, C. M., Hornick, J. L. & Fletcher, C. D. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am. J. Surg. Pathol. 31, 509–520 (2007).
Ma, Z. et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 37, 98–105 (2003).
Debelenko, L. V. et al. Identification of CARS–ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab. Invest. 83, 1255–1265 (2003).
Lamant, L. et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156, 1711–1721 (2000).
Powers, C., Aigner, A., Stoica, G. E., McDonnell, K. & Wellstein, A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 277, 14153–14158 (2002).
Mathivet, T., Mazot, P. & Vigny, M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full-length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? Cell Signal 19, 2434–2443 (2007).
Stoica, G. E. et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 277, 35990–35998 (2002).
Perez-Pinera, P., Zhang, W., Chang, Y., Vega, J. A. & Deuel, T. F. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase β/ζ signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J. Biol. Chem. 282, 28683–28690 (2007).
Pillay, K., Govender, D. & Chetty, R. ALK protein expression in rhabdomyosarcomas. Histopathology 41, 461–467 (2002).
Jazii, F. R. et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of β tropomyosin expression in esophageal cancer. World J. Gastroenterol. 12, 7104–7112 (2006).
Du, X. L. et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J. Mol. Med. 85, 863–875 (2007).
Wellmann, A. et al. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J. 11, 965–972 (1997).
Ambrogio, C. et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood 106, 3907–3916 (2005).
Bai, R. Y., Dieter, P., Peschel, C., Morris, S. W. & Duyster, J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity. Mol. Cell Biol. 18, 6951–6961 (1998).
Bai, R. Y. et al. Nucleophosmin–anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96, 4319–4327 (2000). First identification of PI3K and Akt as downstream effectors of the NPM–ALK anti-apoptotic signalling pathway and their contribution to the molecular pathogenesis of ALCL.
Zamo, A. et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21, 1038–1047 (2002). First report showing that JAK3 and STAT3 are constitutively activated in ALK-positive cells and that activation of STAT3 contributes to the growth and resistance to apoptosis of ALK-positive tumour cells.
Raetz, E. A. et al. The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas. Am. J. Pathol. 161, 875–883 (2002).
Fujimoto, J. et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl Acad. Sci. USA 93, 4181–4186 (1996). First demonstration of the transforming properties of NPM–ALK in vitro in mouse fibroblasts.
Pulford, K., Morris, S. W. & Turturro, F. Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell Physiol. 199, 330–358 (2004).
Voena, C. et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 67, 4278–4286 (2007).
Sattler, M. et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1, 479–492 (2002).
Cussac, D. et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103, 1464–1471 (2004).
Bacchiocchi, R. et al. Activation of α-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. Blood 106, 2175–2182 (2005).
Honorat, J. F., Ragab, A., Lamant, L., Delsol, G. & Ragab-Thomas, J. SHP1 tyrosine phosphatase negatively regulates NPM–ALK tyrosine kinase signaling. Blood 107, 4130–4138 (2006).
Han, Y. et al. Restoration of shp1 expression by 5-aza-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 20, 1602–1609 (2006).
Han, Y. et al. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM–ALK in ALK+ anaplastic large-cell lymphoma. Blood 108, 2796–2803 (2006).
Leventaki, V. et al. NPM–ALK oncogenic kinase promotes cell cycle progression through activation of JNK/c-Jun signaling in anaplastic large cell lymphoma. Blood 110, 1621–1630 (2007).
Ouyang, T. et al. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA). J. Biol. Chem. 278, 30028–30036 (2003).
Bassermann, F. et al. Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J. Biol. Chem. 282, 15965–15972 (2007).
Bassermann, F. et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45–57 (2005).
Gu, T. L. et al. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 103, 4622–4629 (2004).
Zhang, Q. et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 168, 466–474 (2002).
Amin, H. M. et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22, 5399–5407 (2003).
Marzec, M. et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest. 85, 1544–1554 (2005).
Coluccia, A. M. et al. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood 103, 2787–2794 (2004).
Piva, R. et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J. Clin. Invest. 116, 3171–3182 (2006).
Nieborowska-Skorska, M. et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 61, 6517–6523 (2001).
Ruchatz, H., Coluccia, A. M., Stano, P., Marchesi, E. & Gambacorti-Passerini, C. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp. Hematol. 31, 309–315 (2003).
Zhang, Q., Wang, H. Y., Liu, X. & Wasik, M. A. STAT5A is epigenetically silenced by the tyrosine kinase NPM1–ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1–ALK expression. Nature Med. 13, 1341–1348 (2007).
Slupianek, A. et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61, 2194–2199 (2001).
Rassidakis, G. Z. et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 105, 827–829 (2005).
Slupianek, A. & Skorski, T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Exp. Hematol. 32, 1265–1271 (2004).
Marzec, M. et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26, 5606–5614 (2007).
Vega, F. et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 66, 6589–6597 (2006).
Armstrong, F. et al. Differential effects of X–ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23, 6071–6082 (2004).
Motegi, A., Fujimoto, J., Kotani, M., Sakuraba, H. & Yamamoto, T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J. Cell Sci. 117, 3319–3329 (2004).
Horie, R. et al. The NPM–ALK oncoprotein abrogates CD30 signaling and constitutive NF-κB activation in anaplastic large cell lymphoma. Cancer Cell 5, 353–364 (2004).
Colomba, A. et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM–ALK signaling in anaplastic large cell lymphomas. Oncogene (2007).
Bonzheim, I. et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 104, 3358–3360 (2004).
Kasprzycka, M., Marzec, M., Liu, X., Zhang, Q. & Wasik, M. A. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl Acad. Sci. USA 103, 9964–9969 (2006).
Roncador, G. et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 19, 2247–2253 (2005).
Hsu, F. Y., Johnston, P. B., Burke, K. A. & Zhao, Y. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res. 66, 9002–9008 (2006). This paper demonstrates for the first time the functional relationship between NPM–ALK and CD30, identifying JUNB as the mediator of NPM–ALK-dependent CD30 transcriptional regulation.
Watanabe, M. et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed–Sternberg cells of Hodgkin lymphoma. Cancer Res. 65, 7628–7634 (2005).
Horie, R. et al. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin–Reed–Sternberg cells. Oncogene 21, 2493–2503 (2002).
Wright, C. W., Rumble, J. M. & Duckett, C. S. CD30 activates both the canonical and alternative NF-κB pathways in anaplastic large cell lymphoma cells. J. Biol. Chem. 282, 10252–10262 (2007).
Ohno, H., Nishikori, M., Maesako, Y. & Haga, H. Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma. Int. J. Hematol. 82, 397–405 (2005).
Thompson, M. A. et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum. Pathol. 36, 494–504 (2005).
Trempat, P. et al. Gene expression profiling in anaplastic large cell lymphoma and Hodgkin's disease. Leuk. Lymphoma 45, 2001–2006 (2004).
Lamant, L. et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109, 2156–2164 (2007).
Piccaluga, P. P. et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 117, 823–834 (2007).
Rush, J. et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nature Biotechnol. 23, 94–101 (2005).
Elenitoba-Johnson, K. S. et al. Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins. Proc. Natl Acad. Sci. USA 103, 7402–7407 (2006).
Crockett, D. K., Lin, Z., Elenitoba-Johnson, K. S. & Lim, M. S. Identification of NPM–ALK interacting proteins by tandem mass spectrometry. Oncogene 23, 2617–2629 (2004).
Lim, M. S. & Elenitoba-Johnson, K. S. Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma. Mol. Cell Proteomics 5, 1787–1798 (2006).
Fanale, M. A. & Younes, A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67, 333–350 (2007).
Li, R. & Morris, S. W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med. Res. Rev. 10 August 2007 (doi: 10.1002/med.20109).
Galkin, A. V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM–ALK. Proc. Natl Acad. Sci. USA 104, 270–275 (2007).
Wan, W. et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107, 1617–1623 (2006).
Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408–4417 (2007). This paper, and the preceding two, shows the development of the first small molecules with selective ALK inhibitory activity, which result in G1 cell-cycle arrest and inactivation of ERK1 and ERK2, STAT3 and Akt signaling pathways. These results suggest a therapeutic application for ALK-positive ALCL and possibly other solid and haematological tumours in which ALK activation is implicated in their pathogenesis.
Piva, R. et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 107, 689–697 (2006). Proof of principle that ALK is a viable target for therapeutic intervention and that its inactivation might be a pivotal approach for the treatment of ALK lymphomas.
Ait-Tahar, K. et al. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int. J. Cancer 118, 688–695 (2006).
Passoni, L. et al. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica 91, 48–55 (2006).
Pulford, K. et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 96, 1605–1607 (2000).
Lollini, P. L., Cavallo, F., Nanni, P. & Forni, G. Vaccines for tumour prevention. Nature Rev. Cancer 6, 204–216 (2006).
Kim, D. H. & Rossi, J. J. Strategies for silencing human disease using RNA interference. Nature Rev. Genet. 8, 173–184 (2007).
Englund, C. et al. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature 425, 512–516 (2003).
Lee, H. H., Norris, A., Weiss, J. B. & Frasch, M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 425, 507–512 (2003). This paper and the preceding one are the first description of a physiological role of an ALK homologue in Drosophila melanogaster.
Bazigou, E. et al. Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell 128, 961–975 (2007).
Liao, E. H., Hung., W., Abrams, B. & Zhen, M. An SCF-like ubiquitin ligase complex that controls presynaptic differentiation. Nature 430, 345–350 (2004).
Vernersson, E. et al. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 6, 448–461 (2006).
Morris, S. W. et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14, 2175–2188 (1997).
Iwahara, T. et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439–449 (1997).
Souttou, B., Carvalho, N. B., Raulais, D. & Vigny, M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 276, 9526–9531 (2001).
Piccinini, G. et al. A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. J. Biol. Chem. 277, 22231–22239 (2002).
Bilsland, J. G. et al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology 9 May 2007 (doi: 10.1038/sj.npp.1301446).
Yang, H. L. et al. The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK. J. Exp. Zoolog. B Mol. Dev. Evol. 308, 269–282 (2007).
Stoica, G. E. et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276, 16772–16779 (2001).
Mi, R., Chen, W. & Hoke, A. Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc. Natl Acad. Sci. USA 104, 4664–4669 (2007).
Mourali, J. et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol. Cell Biol. 26, 6209–6222 (2006).
Moog-Lutz, C. et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280, 26039–26048 (2005).
Miyake, I. et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21, 5823–5834 (2002).
Sebti, S. M. & Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584–6593 (2000).
Hudes, G. et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
Siddiquee, K. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA 104, 7391–7396 (2007).
Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875–878 (2003).
Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).
Tran, H., Brunet, A., Griffith, E. C. & Greenberg, M. E. The many forks in FOXO's road. Sci. STKE 2003, re5 (2003).
Dijkers, P. F. et al. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J. Cell Biol. 156, 531–542 (2002).
Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053–4062 (2006).
Shiota, M. et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86, 1954–1960 (1995).
Adam, P. et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am. J. Surg. Pathol. 27, 1473–1476 (2003).
Onciu, M. et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM–ALK fusion transcript: report of 2 cases. Blood 102, 2642–2644 (2003).
Lamant, L., Dastugue, N., Pulford, K., Delsol, G. & Mariame, B. A new fusion gene TPM3–ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93, 3088–3095 (1999).
Siebert, R. et al. Complex variant translocation t(1;2) with TPM3–ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma. Blood 94, 3614–3617 (1999).
Hernandez, L. et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG–ALK translocations. Blood 94, 3265–3268 (1999).
Trinei, M. et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC–ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 60, 793–798 (2000).
Bridge, J. A. et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am. J. Pathol. 159, 411–415 (2001).
Reichard, K. K., McKenna, R. W. & Kroft, S. H. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod. Pathol. 20, 310–319 (2007).
Tort, F., Campo, E., Pohlman, B. & Hsi, E. Heterogeneity of genomic breakpoints in MSN–ALK translocations in anaplastic large cell lymphoma. Hum. Pathol. 35, 1038–1041 (2004).
Meech, S. J. et al. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion. Blood 98, 1209–1216 (2001).
Cools, J. et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34, 354–362 (2002).
Lamant, L. et al. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 37, 427–432 (2003).
Stachurski, D. et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3′ ALK gene insertion to chromosome 4 q22–24. Hum. Pathol. 38, 940–945 (2007).
Panagopoulos, I. et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int. J. Cancer 118, 1181–1186 (2006).
This work was supported by National Institutes of Health grant number R01-CA64033, Sixth Research Framework Program of the European Union, Project RIGHT (LSHB-CT-2004-005276), Ministero dell'Università e Ricerca Scientifica (MUR), Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro, Regione Piemonte, Compagnia di San Paolo Torino (Progetto Oncologia), Fondazione Cassa di Risparmio di Torino and Fondazione Guido Berlucchi per la Ricerca sul Cancro. Roberto Piva was supported by the MUR programme 'Incentivazione alla mobilità di studiosi residenti all'estero'. Claudia Voena was supported by a fellowship from the Fondazione Italiana per la Ricerca sul Cancro.
The authors declare no competing financial interests.
Morphology and dynamics of untreated anaplastic large cell lymphoma (ALCL) cells. Untreated human ALCL cells were photographed with confocal microscopy every 5 min. ALCL cells spontaneously display an activated-like T-cell morphology, with actin-rich membrane protrusions. The high dynamics of the membrane protrusions is a typical feature of ALCL cells. (MOV 7736 kb)
Changes in morphology and dynamics of anaplastic large cell lymphoma (ALCL) cells after anaplastic lymphoma kinase (ALK) inhibition. Human ALCL cells were treated with the specific ALK inhibitor and photographed with confocal microscopy every 5 min. On treatment with ALK inhibitor, ALCL cells first revert to a round, symmetrical shape and lose their membrane protrusions. Subsequently, after a prolonged treatment, ALCL cells undergo apoptosis. (MOV 4693 kb)
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Loss of structural differentiation within a cell or group of cells, often with increased capacity for multiplication, as in a malignant tumour.
A general term for cells of monocytic lineage. When histiocytes show evident phagocytic activity they are called macrophages. For tumours, the term histiocytic refers either to a proven or supposed derivation of the neoplastic cells from normal hystiocytes or to tumours in which neoplastic cells are mixed with abundant reactive histiocytes.
- Pseudonuclear inclusions
A peculiar aspect of cells in which the nucleus appears to enclose a region of cytoplasm within a ring; such cells are called doughnut cells.
- Immunoblastic or plasmablastic morphology
Morphology that resembles plasmablasts. Plasmablasts are cells that have the blastoid morphology of immunoblasts but have acquired the antigen profile of a plasma cell. They are large cells with abundant basophilic cytoplasm and round to oval nuclei with single or several prominent nucleoli.
- Dependence receptor
A transmembrane protein that is capable of inducing cell death in the absence of the required stimulus but which blocks apoptosis following binding to their ligand. Expression of these receptors creates cellular states of dependence on the associated ligands.
- WD domain
WD repeats are short amino-acid motifs terminating in Trp–Asp (W–D). WD domain-containing proteins have 4 to 16 repeating units and are implicated in signal transduction, transcription regulation, cell-cycle control and apoptosis.
- Guanine nucleotide exchange factor
(GEF). A regulatory molecule that catalyses the exchange of GDP for GTP on GTPases in response to diverse extracellular stimuli, and ultimately regulates numerous cellular responses such as proliferation, differentiation and movement.
- GTPase-activating protein
(GAP). A regulatory molecule that enhances the intrinsic GTPase activity of GTPase proteins.
- Reed–Sternberg cell
Diagnostic giant cell of B lineage found in Hodgkin lymphoma. It is characterized by multiple or multilobulated nuclei and prominent eosinophilic nucleoli.
About this article
Cite this article
Chiarle, R., Voena, C., Ambrogio, C. et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8, 11–23 (2008). https://doi.org/10.1038/nrc2291
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer
Journal of Experimental & Clinical Cancer Research (2022)
Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
Diagnostic Pathology (2022)
Nature Reviews Clinical Oncology (2022)